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A QUALITATIVE STUDY OFTHE INDIVIDUALISED IMPACT OF
RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE
Speight J, Reaney M, Showumni O
AHP Research Ltd, Uxbridge, Middlesex, UK
OBJECTIVES: Restless Legs Syndrome (RLS) is a neurological
movement disorder characterised by uncomfortable leg sensa-
tions when at rest, exacerbated in the evening/at night, and
alleviated by movement. A systematic literature review demon-
strated the need for a new RLS-speciﬁc QoL instrument. This
interview study forms the second step in instrument develop-
ment. METHODS: The Schedule for the Evaluation of Individual
Quality of Life (SEIQoL) was used to identify aspects of life that
are most important for individuals’ QoL, rank their relative
importance and then rate them in terms of impact by RLS. We
adapted the SEIQoL to be RLS-speciﬁc and suitable for telephone
administration. Twenty-six participants (mean age 61 years
(range 32–83 years); 58% female) were recruited from the
Ekbom Society, the UK’s RLS patient support group. Telephone
interviews (mean duration 54 mins (range 31–83 mins)),
included the adapted SEIQoL and semi-structured questions
about experience of RLS and its treatment. RESULTS: The
adapted SEIQoL was acceptable to participants and facilitated an
individualised investigation of the impact of RLS on QoL. On
average, participants had experienced RLS symptoms for 22
years (range: 6 months to 65 years), though 35% had never
received a diagnosis from their doctor. Most participants
described their symptoms as severe (73%) and occurring daily
(88%). General aspects of life impacted by RLS included family,
health, hobbies, spirituality and social life, as well as some areas
that may be more speciﬁc to living with RLS (physical ability,
stress and sleep). CONCLUSION: RLS had an adverse impact on
most aspects of life nominated by individuals as important for
their QoL. This study supports our previous literature review,
which indicated that QoL is impacted in many ways that are
important to the individual and rarely assessed in existing mea-
sures. These results will be used to develop a comprehensive
measure of the impact of RLS on QoL.
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MEASURINGTHE IMPACT OF RESTLESS LEGS SYNDROME
(RLS) ON QUALITY OF LIFE: A SYSTEMATIC REVIEW
Speight J, Reaney M, Showumni O
AHP Research Ltd, Uxbridge, Middlesex, UK
OBJECTIVES: Restless Legs Syndrome (RLS) is a neurological
movement disorder affecting 5–15% of the general population.
Given its subjective nature, it is important to assess the impact of
RLS from the patient’s perspective. The objective of the literature
review was to identify and assess the suitability of instruments
used to measure the impact of RLS on quality of life (QoL).
METHODS: Systematic searches of Medline and PsycINFO were
conducted using terms synonymous with “RLS” in combination
with terms associated with measuring “QoL”. RESULTS: Two
hundred and six abstracts were identiﬁed and screened. Of these,
21 reported quantitative studies using a variety of measures (i.e.
generic health status, RLS-speciﬁc health status, symptoms and
emotional well-being, anxiety/depression and fatigue/sleep),
despite almost all abstracts referring to the measurement of
“QoL”. Generic measures, such as the SF-36 can be useful when
making comparisons with other medical conditions but have
limited value for assessing the full impact of RLS because they
include irrelevant items (e.g. mobility, which is likely to relieve
symptoms) and exclude relevant issues (e.g. impact on sleep,
working life). The RLS-speciﬁc symptom measure (the IRLS) is
often misinterpreted as measuring QoL rather than symptoms.
Recently, the RLSQOL and RLSQLI have been developed to
measure the impact of RLS on QoL. Despite displaying adequate
psychometric properties and assessing some facets of QoL
impacted by RLS, these also do not assess the full range of
aspects of life affected by RLS. CONCLUSION: This review
concludes that existing generic and RLS-speciﬁc measures are
likely to underestimate the full impact of RLS on QoL and,
therefore, underestimate the full potential beneﬁts of new treat-
ments. In addition, they rarely offer opportunities for patients to
indicate any perceived beneﬁts of the condition. A new question-
naire is needed to assess the full impact (both positive and nega-
tive) of RLS on QoL.
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FIT OFTHE MIGRAINE PREVENTION ASSESSMENT CLINICAL
TOOL (M-PACT) WITH QUALITATIVE DEVELOPMENT
GUIDELINES FOR PATIENT REPORTED OUTCOMES
Cole JC1, Lin P1, Kite A1, Caleo S2
1QualityMetric, Lincoln, RI, USA, 2Johnson & Johnson Pharmaceuticals,
Belguim, Beerse, Belgium
OBJECTIVES: Guidance from European and U.S. regulatory
agencies regarding Patient Reported Outcomes (PROs) has
afforded greater clarity on various aspects of instrument develop-
ment. As no current measures of migraine Quality of Life (QoL)
impact have addressed issues related to prophylactic treatment,
the M-PACT was developed as a PRO tool to evaluate this aspect
of migraine-impacted QoL. The current abstract provides details
on the ﬁt of theM-PACTwith qualitative development guidelines.
METHODS: An exhaustive review of the literature was ﬁrst
conducted to identify pertinent PRO instruments or items.
Experts in migraine were gathered for additional input on the
domains and format of the PRO. Next, patient (i.e., migraineurs)
focus groups were held to understand the patient-perceived appli-
cability of domains as well as to generate item language. With the
introduction of EULA and FDA guidance documents during
development of the M-PACT, item anchors and test instructions
were reﬁned. The ﬁnal format of the M-PACT was evaluated by
experts in migraine and with migraine and headache sufferers
through cognitive interviews. RESULTS: The multiple modalities
of conceptual framework development yielded a total of 21 items
covering 4 related domains (daily activities, emotional stability,
concentration, and social interaction), all subsumed under a
single factor of migraine-related QoL impact. An overabundance
of items was speciﬁcally sought to allow for selection of the best
items during quantitative analysis ofM-PACT. Feedback from the
cognitive interviews conﬁrmed these questions as relevant and
easy to understand CONCLUSION: The M-PACT questionnaire
was developed following a sequential, multistep, multisource
approach for questionnaire development. Given the strong
synergy between key opinion leaders, migraineurs, and the litera-
ture, the M-PACT PRO is expected to be an effective measure to
assess QoL impact on migraineurs undergoing prophylactic treat-
ment. Quantitative validation of the M-PACT is underway.
Overall, the M-PACT ﬁts well with qualitative development
guidelines.
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A REVIEW OF PATIENT-REPORTED OUTCOMESTHAT
COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN
ADULT EPILEPSY DRUGTRIALS
Hoffman DL1, Mychaskiw MA2
1Deborah Hoffman, PhD, LLC, New Haven, CT, USA, 2Pﬁzer, Inc, New
York, NY, USA
OBJECTIVES: 1) To identify patient-reported outcomes used to
complement assessments of seizure reduction in adult epilepsy
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drug trials; 2) to identify trials that speciﬁcally examined the
impact of treatment on patient-reported anxiety, depression and
sleep disturbance, as these common comorbid symptoms are
associated with poorer health status in people with epilepsy; and,
3) to identify which measures/domains were most responsive to
change. METHODS: A review of 41 adult epilepsy trials exam-
ining the impact of an oral antiepileptic drug on patient-reported
assessments of anxiety, depression, well-being, sleep, function
and treatment satisfaction. Studies were identiﬁed through
searches in MEDLINE, the Cochrane Central Register of Con-
trolled Trials and reference lists of published articles. RESULTS:
The most common types of PROs comprised epilepsy-speciﬁc
measures assessing multiple domains of functioning and well-
being (used in 30 studies) and generic measures assessing anxiety/
depression and other emotions (used in 21 studies). There was
limited detection of treatment effect on scales assessing anxiety/
depression and emotional well-being. Scales assessing per-
ceptions of emotional well-being were more likely to show
signiﬁcant differences than measures assessing symptom severity.
Patients were not required to have clinically signiﬁcant anxiety/
depression to participate. It is possible that patients entered trials
with symptoms in the normal range, leaving no room to show
improvement; that treatment did not worsen symptoms; or, that
instruments were not responsive. Findings were mixed regarding
other speciﬁc health status domains. Patients receiving active
treatments typically reported signiﬁcantly higher levels of satis-
faction than those receiving placebo. Only 2 trials were identiﬁed
that assessed patient-reported sleep, but both showed signiﬁcant
differences on speciﬁc domains. CONCLUSION: Anxiety and
depression were among the most common PROs assessed, but
there was limited detection of treatment effect. Trial selection
criteria complicate interpretation of ﬁndings. Patient-reported
sleep outcomes were rarely studied, but deserve more attention in
adult epilepsy drug trials.
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LONGITUDINAL PATIENT-REPORTED OUTCOMES (PRO) IN
SUBJECTS WITH REFRACTORY PAIN ASSOCIATEDTO
TRIGEMINAL NEURALGIA:A POST-HOC ANALYSIS OF A
12-WEEK PROSPECTIVE STUDY IN PRIMARY CARE SETTING
(PCS) UNDER ROUTINE MEDICAL PRACTICE
Saldaña MT1, Pérez C2, Navarro A3, Martínez S4, Rejas J5
1Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 2Hospital
University La Princesa, Madrid, Spain, 3Primary Care Centre “Puerta
del Ángel”, Madrid, Spain, 4European Biometrics Institute, Barcelona,
Spain, 5Pﬁzer Spain, Madrid, Spain
OBJECTIVES: To analyze longitudinal PRO measurements evo-
lution after treating refractory pain due to Trigeminal Neuralgia
in Primary Care Setting (PCS) during 12-weeks under routine
medical practice. METHODS: Sub-analysis of a sample of
patients above 18 years, with 6-month chronic pain due to
trigeminal neuralgia refractory to, at least, one previous analgesic
[previous mean (SD) number of drugs was 2.2 (1.2), with a
36.3% on one-drug only], included in a prospective, naturalistic,
12-weeks two-visit study on refractory peripheral Neuropathic
pain. PRO measurements included pain severity by McGill-pain
scale (included 50%-reduction responder rate and days with
no/mild pain), anxiety and depression symptoms (HAD scale),
sleep disturbances (MOS-sleep), disability (Sheehan scale), and
quality-adjusted-life-year (QALY) gain (EQ-5D). Paired non-
parametric and t-tests were applied. RESULTS: Ninety-one
[62.2% women, 57.7 (13.9) years] patients were analyzed: 45%
switched to pregabalin as a monotherapy, 37% received pregaba-
lin as add-on therapy, and in 18% previous treatment was
replaced by a regimen not including pregabalin. After 12 weeks
of therapy, signiﬁcant reduction in last-week mean pain severity
[-35.0 (23.9) mm, p < 0.0001, 53.9% responders] and percent-
age of subjects declaring the pain as severe or worst from 60.5%
to 10.5% (p < 0.0001), was accompanied by reductions in total
disability score [-8.2 (6.0) pts, p < 0.0001], depression symp-
toms score [-3.8 (4.2) pts, p < 0.0001], anxiety symptoms score
[-3.4 (3.3) pts, p < 0.0001], and summary-index sleep problems
scoring [-16.5 (18.4), p < 0.0001], while treatment increased the
quarterly mean number of days with no/mild pain [+32.3 (28.9)
days, p < 0.0001], the average number of sleeping-hours per
night [+0.8 (1.3), p < 0.0001], and produced a QALY gain of
0.0317 (0.0385). CONCLUSION: A therapy mix of painful
trigeminal neuralgia mostly based on pregabalin (82% of cases)
was associated with a signiﬁcant longitudinal improvement in
patient-reported-outcomes including severity of pain, symptoms
of depression and anxiety, disability, sleep disturbance and
quality-adjusted-life-year gain.
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PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN
PARKINSON’S DISEASE: OVERVIEW OF US AND EUROPEAN
DRUG APPROVALS
Caron M1, Emery MP1, Marquis P2, Piault E2
1Mapi Research Trust, Lyon, France, 2Mapi Values, Boston, MA, USA
OBJECTIVES: To review the Parkinson’s disease products
approved both in the United States (US) and in Europe with a
particular focus on the PRO end-points appearing in the prod-
ucts’ labels. METHODS: Parkinson’s disease products approved
in Europe since 1995 through the centralized procedure and in
the US since 1998 (new molecular entities) were identiﬁed from
a review of the EMEA and FDA websites. Using the PROLabels
database, we then identiﬁed the products indicated for Parkin-
son’s disease treatment and showing evidence of PRO in labeling.
PROLabels is a unique on-line tool which provides information
on the drug products for which the FDA and/or the EMEA have
granted PRO labeling claims. RESULTS: Overall, 10 different
products indicated for the treatment of Parkinson’s disease wAS
identiﬁed in this review, accounting for 7 different molecules. Of
these 10 drugs, 9 demonstrated the efﬁcacy of the treatment using
PRO endpoints. We will focus here on the 3 active molecules
approved both in Europe and in the US with a PRO labeling
claim. All six dossiers report the use of patient diaries to record
ON- and OFF-times. Other PRO endpoints assessed were health-
related quality of life (HRQL) and activities of daily living (ADL)
in two cases, and global functioning and levodopa dose in one
case. Regarding the methods of PRO measure, 4 products used a
deﬁned instrument to capture ADL and HRQL, and one used a
single item to assess functioning. CONCLUSION: Overall, PRO
data in labeling for Parkinson’s disease products is quite frequent
(in 9 out of 10 approved products), and above the average rate
over all therapeutic areas (source PROLabels). PRO endpoints
appeared mainly in the clinical studies section of the product
label. An interesting ﬁnding is the discrepancy between the
American and the European PRO claims.
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